Esthesioneuroblastoma

Heidi D. Klepin, Kevin P. McMullen, Glenn J. Lesser

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.

Original languageEnglish (US)
Pages (from-to)509-518
Number of pages10
JournalCurrent Treatment Options in Oncology
Volume6
Issue number6
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Olfactory Esthesioneuroblastoma
Therapeutics
Radiation
Drug Therapy
Salvage Therapy
Combination Drug Therapy
Disease-Free Survival
Neoplasms
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Klepin, H. D., McMullen, K. P., & Lesser, G. J. (2005). Esthesioneuroblastoma. Current Treatment Options in Oncology, 6(6), 509-518. https://doi.org/10.1007/s11864-005-0029-7

Esthesioneuroblastoma. / Klepin, Heidi D.; McMullen, Kevin P.; Lesser, Glenn J.

In: Current Treatment Options in Oncology, Vol. 6, No. 6, 11.2005, p. 509-518.

Research output: Contribution to journalArticle

Klepin, HD, McMullen, KP & Lesser, GJ 2005, 'Esthesioneuroblastoma', Current Treatment Options in Oncology, vol. 6, no. 6, pp. 509-518. https://doi.org/10.1007/s11864-005-0029-7
Klepin, Heidi D. ; McMullen, Kevin P. ; Lesser, Glenn J. / Esthesioneuroblastoma. In: Current Treatment Options in Oncology. 2005 ; Vol. 6, No. 6. pp. 509-518.
@article{c0d81358725e484986059731dff32b42,
title = "Esthesioneuroblastoma",
abstract = "Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.",
author = "Klepin, {Heidi D.} and McMullen, {Kevin P.} and Lesser, {Glenn J.}",
year = "2005",
month = "11",
doi = "10.1007/s11864-005-0029-7",
language = "English (US)",
volume = "6",
pages = "509--518",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Esthesioneuroblastoma

AU - Klepin, Heidi D.

AU - McMullen, Kevin P.

AU - Lesser, Glenn J.

PY - 2005/11

Y1 - 2005/11

N2 - Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.

AB - Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.

UR - http://www.scopus.com/inward/record.url?scp=29844438767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29844438767&partnerID=8YFLogxK

U2 - 10.1007/s11864-005-0029-7

DO - 10.1007/s11864-005-0029-7

M3 - Article

C2 - 16242055

AN - SCOPUS:29844438767

VL - 6

SP - 509

EP - 518

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 6

ER -